I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

September 22, 2003

Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 C.F.R. § 1.116 Examining Group 1644 Patent Application Docket No. SPO-103 Serial No. 09/142,524

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Marianne N. DiBrino, Ph.D.

Art Unit

1644

Applicants

Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama,

Kohsuke Kino

Serial No.

09/142,524

Filed

September 9, 1998

Confirm, No.:

2300

For

Peptide-Based Immunotherapeutic Agent for Treating Allergic

Diseases

Mail Stop AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## AMENDMENT UNDER 37 C.F.R. § 1.116

A Petition and Fee for a one-month Extension of Time through and including September 21, 2002, a accompanies this Amendment.

In response to the Offic Action May 21, 2003, please amend the above-identified application as follows:

J:\Spo\103\AFResponse-.doc\DNB\ssa

FAX NO. 352 372 5800

P. 01
PECEIVED

SEP 2 2 2003

## FACSIMILE COVER SHEET

## SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association 2421 N.W. 41<sup>st</sup> Street Suite A-1 Gainesville, FL 32606

Telephone (352) 375-8100 Facsimile (352) 372-5800

TO: Examiner Marianne DiBrino

FROM:

Frank C. Eisenschenk, Ph.D.

COMPANY:

U.S. Patent Office, Art Unit 1644

DATE:

September 22, 2003

FAX NO.:

1-703-872-9306

NO. OF PAGES:

(INCLUDING COVER SHEET)

MSUBJECT/MESSAGE:

U.S. Patent Application Docket No. SPO-103

Peptide-Based Immunotherapeutic Agent for Treating Allergic

Diseases (Sone, et al.)

Serial No. 09/142,524; Filed September 9, 1998

**ATTACHMENT:** 

Petition and Fee for Extension of Time Under 37 C.F.R. § 1.136(a)

Amendment Under 37 C.F.R. § 1.116

THIS IS A DUALT AMENDMENT FOR

**DISCUSSION PURPOSES ONLY** 

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

J:\Spo\103\Fax2Examiner.doc/DNB/ssa